this post was submitted on 01 Nov 2023
440 points (99.3% liked)
Technology
59451 readers
3805 users here now
This is a most excellent place for technology news and articles.
Our Rules
- Follow the lemmy.world rules.
- Only tech related content.
- Be excellent to each another!
- Mod approved content bots can post up to 10 articles per day.
- Threads asking for personal tech support may be deleted.
- Politics threads may be removed.
- No memes allowed as posts, OK to post as comments.
- Only approved bots from the list below, to ask if your bot can be added please contact us.
- Check for duplicates before posting, duplicates may be removed
Approved Bots
founded 1 year ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
LMAO
Goldman Sachs: "Is curing patients a sustainable business model?"
Not if Wall Street has anything to do with it!
We may and should point to all questionably bad practices of these drug companies, but I think humanity is still far better off with their research advancements than without them. So I'm all for using my data for that purpose like 23andMe is doing. Now insurance companies and lobbyists - these can go to hell.
If you can keep someone from dying by being dependent on only your medication, you've created a customer for life rather than one who died and didn't give you all their money to live another day.
The name of the report is horrific, but a little misleading with just the title. It's specifically a report about gene therapies, which are obviously still happening. Just look at spinal muscular atrophy, Duchene muscular dystrophy, sickle cell anemia about to be approved, and many others already approved or well on their way.
The main points of the report are a little more benign than the title of the report would suggest and are mostly making suggestions on how to keep a biotech company that is focused on developing cures for rare diseases solvent and running. Their main suggestions were to have a mix of both common and rare diseases, prioritizing diseases with high morbidity (like spinal muscular atrophy), and to keep a constant pipeline of new cures coming out for more rare diseases.
Don't get me wrong I have many issues with big pharma, but the way that analyst's report title gets used is very misleading.